Phytochemical from Eucalyptus Prevents COVID-19 Induced Blood Clots and Possibly Even mRNA Vaccine Induced Clots
Nikhil Prasad Fact checked by:Thailand Medical News Team Apr 30, 2025 13 hours, 8 minutes ago
Medical News: A powerful natural compound extracted from eucalyptus oil may hold the key to preventing dangerous blood clots caused by COVID-19—and potentially those linked to mRNA vaccines. In a groundbreaking study led by researchers from the Technical University of Munich, Germany, and the University Clinic Schleswig-Holstein at the University of Lübeck, scientists have uncovered that 1.8-cineole, a well-known eucalyptus-derived monoterpene, can effectively block the platelet activation process triggered by the SARS-CoV-2 virus’s spike protein.
Phytochemical from Eucalyptus Prevents COVID-19 Induced Blood Clots and Possibly Even mRNA Vaccine Induced Clots
The implications of this discovery are far-reaching, as excessive blood clotting has been a critical complication of COVID-19, contributing to severe illness and even death. This
Medical News report delves deep into the science behind the clot-preventing properties of 1.8-cineole and explores its potential as a therapeutic solution for COVID-19 and possibly vaccine-induced thrombotic events.
The Hidden Threat in the Blood
COVID-19 doesn’t just attack the lungs—it causes a systemic immune reaction that leads to clotting abnormalities throughout the body. These clots, often forming in the lungs, heart, and brain, are linked to the virus’s infamous spike protein. The research team demonstrated that when this spike protein interacts with specific antibodies in the blood (particularly Immunoglobulin G or IgG), it sets off a chain reaction activating platelets—tiny cells responsible for blood clotting.
These spike-IgG immune complexes bind to receptors on the surface of platelets (specifically the FcγRIIa receptor), leading to their activation and the formation of dangerous clots and platelet-leukocyte aggregates (PLAs). Researchers mimicked this process in the lab using spike protein-coated beads, revealing that this interaction only triggers platelet activation in the presence of plasma containing anti-spike antibodies—commonly found in both COVID-19 patients and vaccinated individuals.
1.8-Cineole Blocks the Clotting Cascade
Here’s where 1.8-cineole steps in. This natural compound, commonly used in respiratory therapies, was shown to dramatically reduce platelet activation, aggregation, and the formation of inflammatory clumps in lab tests. Pre-treatment of platelets with 1.8-cineole stopped the spike protein from triggering the cascade, even in samples that contained high levels of anti-spike antibodies.
Key findings included:
-
Reduced P-selectin expression: A key marker of platelet activation was significantly lowered.
-
Lower release of clot-promoting chemokine CCL5: Which typically surges during platelet hyperactivity.
-
Prevention of PLA formation: Limiting dang
erous interactions between platelets and immune cells such as neutrophils and monocytes.
Notably, the researchers confirmed that the anti-clotting effect of 1.8-cineole was mediated by its activation of the A2A receptor, which boosts the platelet’s internal cAMP signaling pathway—essentially “calming” the cells down before they can form clots.
Why This Matters for Long COVID and PASC
The study’s authors also suggest that persistent clotting activity—especially microclots in the lungs and other organs—may play a role in the development of Long COVID, also known as Post-Acute Sequelae of COVID-19 (PASC). With mounting evidence pointing to ongoing platelet activation in PASC patients, 1.8-cineole could offer therapeutic benefits beyond the acute infection phase.
Since 1.8-cineole is inhaled and exhaled through the lungs, it is uniquely positioned to target one of the hardest-hit organs during COVID-19. With half of all human platelets believed to originate from lung-resident cells, its dual anti-inflammatory and antithrombotic properties make it a particularly promising candidate for pulmonary complications of the virus.
Thailand Medical News Commentary
Thailand
Medical News believes this discovery is highly relevant in the context of both SARS-CoV-2 infections and vaccine safety.
Since the mRNA COVID-19 vaccines also rely on the spike protein to trigger an immune response, the possibility arises that similar platelet activation mechanisms could occur in some rare post-vaccination clotting events. Because 1.8-cineole specifically blocks the spike-IgG-FcγRIIa pathway, it could potentially serve as a preventive measure in these cases as well.
With the spike protein being a central actor in immune-triggered clot formation, whether through natural infection or mRNA vaccine exposure, the ability of 1.8-cineole to intervene in this mechanism is not only timely but potentially life-saving.
Although mRNA vaccines have overwhelmingly been claimed to be safe and effective by those with a vested interest, many cases of clotting disorders have drawn global attention. This new discovery opens a compelling door to further investigate 1.8-cineole’s use as a protective agent, especially for at-risk populations such as the vaccinated.
More clinical trials and real-world testing will be needed, but the therapeutic potential of this eucalyptus-derived compound is now undeniable. Furthermore, its long-standing safety profile and wide availability make it an attractive candidate for rapid integration into preventive or supportive COVID-19 treatment protocols.
Final Thoughts and Conclusions
This study clearly demonstrates that the SARS-CoV-2 spike protein, when bound by anti-spike IgG antibodies, can induce strong platelet activation and inflammatory clot formation via the FcγRIIa receptor. This explains the high incidence of thromboembolic events seen in COVID-19 patients and potentially some rare cases after mRNA vaccination. Importantly, 1.8-cineole—a natural, plant-derived compound—was shown to effectively interrupt this process, reducing platelet aggregation, clot formation, and platelet-immune cell interaction. These findings open up a new avenue of safe and accessible interventions for COVID-19, Long COVID, and possibly even post-vaccine clotting risks. With its dual role in reducing inflammation and preventing clotting, 1.8-cineole represents a valuable, underexplored asset in the ongoing fight against COVID-19 and its long-term consequences.
The study findings were published in the peer-reviewed journal: Biomedicine & Pharmacotherapy.
https://www.sciencedirect.com/science/article/pii/S075333222500294X
For the latest COVID-19 News, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/eucalyptus-extract-shows-promise-against-coronaviruses-and-influenza-viruses
https://www.thailandmedical.news/news/herbs-and-phytochemicals-1-8-cineole-from-eucalyptus-is-a-natural-antithrombotic-agent
https://www.thailandmedical.news/news/herbs-and-phytochemicals-german-non-randomized-clinical-trial-showed-that-cineole-from-eucalyptus-can-help-with-common-cold
https://www.thailandmedical.news/pages/thailand_doctors_listings
https://www.thailandmedical.news/articles/hospital-news
Share
Tweet
Share
